WallStSmart

C4 Therapeutics Inc (CCCC)vsInsmed Inc (INSM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 1587% more annual revenue ($606.42M vs $35.95M). INSM leads profitability with a -2.1% profit margin vs -2.9%. INSM earns a higher WallStSmart Score of 39/100 (F).

CCCC

Hold

37

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 5.0

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CCCC2 strengths · Avg: 10.0/10
Price/BookValuation
0.9x10/10

Reasonable price relative to book value

Revenue GrowthGrowth
112.8%10/10

Revenue surging 112.8% year-over-year

INSM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

CCCC4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$263.46M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-44.4%2/10

ROE of -44.4% — below average capital efficiency

Free Cash FlowQuality
$-22.16M2/10

Negative free cash flow — burning cash

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CCCC

The strongest argument for CCCC centers on Price/Book, Revenue Growth. Revenue growth of 112.8% demonstrates continued momentum.

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bear Case : CCCC

The primary concerns for CCCC are EPS Growth, Market Cap, Return on Equity.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Key Dynamics to Monitor

CCCC profiles as a hypergrowth stock while INSM is a turnaround play — different risk/reward profiles.

CCCC carries more volatility with a beta of 2.94 — expect wider price swings.

CCCC is growing revenue faster at 112.8% — sustainability is the question.

CCCC generates stronger free cash flow (-22M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 37/100). Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

C4 Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

C4 Therapeutics, Inc., a biopharmaceutical company, develops new therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. The company is headquartered in Watertown, Massachusetts.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Want to dig deeper into these stocks?